Pinealon (sequence Glu-Asp-Arg, EDR) is a synthetic tripeptide originating from the St. Petersburg Institute of Bioregulation and Gerontology in Russia, with research focusing on neuroprotection and intervention for brain aging. However, its regulatory status and safety evidence are subject to significant uncertainty. As of 2026, Pinealon has not received any marketing approval for human therapeutic indications in any major jurisdiction worldwide (US FDA, EU EMA, UK MHRA, Australian TGA, and Canadian Health Canada), and no Phase I human safety studies have been published in peer-reviewed English journals. Therefore, discussions of its "contraindications" must be based on mechanistic deductions and the lack of evidence.
I. Absolutely Prohibited Scenarios: Based on Clear Lack of Evidence or Known Risks
1. Pregnant and Lactating Women
Reason for Prohibition: Pinealon completely lacks reproductive and developmental toxicology data. Its Safety Data Sheet (SDS) clearly states the risk phrase R63 – "Possible risk of harm to the unborn child" and R62 – "Possible risk of impaired fertility." Pinealon is also presumed to possess epigenetic DNA/histone interactions and activation of proliferative signaling pathways, posing a theoretical developmental risk. Until sufficient reproductive toxicity data are available, pregnant and lactating women should be strictly prohibited from use.
2. History of active or recent malignant tumors
Reason for prohibition: Pinealon exerts its anti-apoptotic effect by inhibiting caspase-3 expression and may activate the MAPK/ERK signaling pathway – a central pathway in cell proliferation and survival. This mechanism is valuable in a neuroprotective context, but poses a theoretical risk in a tumor biology context: inhibition of apoptosis may allow damaged cells to survive, while activation of proliferative signaling may support tumor cell growth. In vitro studies by the National Institutes of Health (NIH) describe caspase-3 inhibition as a "double-edged sword"-neuroprotection and tumor support at opposite ends of the same mechanism. While direct oncogenic signaling has not been confirmed, the gene regulatory effects of pinealon are completely unassessed in the oncology context.
II. Scenarios Requiring Extreme Caution: Theoretical Risks Based on Mechanistic Deductions
3. Patients with Type 1 Diabetes or Glycemic Fragility
Pineealon may participate in lipid and glucose metabolism regulation by affecting APOE expression, and SOD2 promoter binding suggests it may affect redox balance. For patients with type 1 diabetes, any unassessed metabolic regulator may disrupt the already fragile glycemic balance. In the absence of human pharmacokinetic data (absorption, distribution, metabolism, and excretion are not characterized), its use should be avoided until sufficient safety evidence is obtained.
4. Patients with Autoimmune Neurological Disorders
Pinealon, belonging to the short peptide class, can alter glial cytokine programming through the NFκB/ERK/JNK/SMAD pathway and may affect T/B lymphocyte receptor expression and neutrophil phagocytic activity. This immunomodulatory potential poses an unpredictable risk of activation or inhibition in neuroimmune diseases such as multiple sclerosis and autoimmune encephalomyelitis. In the absence of complete immunological safety data, this medication should be avoided in such patients.
5. Patients Currently Using Central Nervous System Active Drugs
Pinealon has prevented dendritic spine loss and normalized long-term potentiation (LTP) in a mouse model of Alzheimer's disease, suggesting a clear regulatory role in synaptic plasticity. This poses a potential risk of additive or antagonistic interactions with antidepressants, antipsychotics, anticonvulsants, and cognitive enhancers. Furthermore, pinearon may affect the melatonin pathway, with theoretical interactions with sedative-hypnotic drugs or exogenous melatonin supplements. No drug interaction studies have been published to date.
6. Individuals with weakened immune systems or those currently using immunosuppressants: Pinealon inhibits the reactive oxygen species (ROS) respiratory burst in neutrophils, an effect that theoretically could impair neutrophil bactericidal activity. For HIV-infected individuals, organ transplant recipients, and patients undergoing chemotherapy or biologic therapy, this immunomodulatory effect may compound immunosuppression, increasing the risk of infection. Caution should be exercised until immunological safety data are available.
7. Athletes: Pinealon has been added to the World Anti-Doping Agency (WADA) Prohibited List Category S0 (Unapproved Substance) for 2026. Competitive athletes are prohibited from using it under any circumstances; this ban is independent of health considerations.
III. "Hidden Forbidden Zones" Due to Lack of Evidence
8. All populations requiring clearly defined dose and safety boundaries: Currently, there are no peer-reviewed human dose-finding studies to determine the minimum effective dose or maximum tolerated dose of Pinealon. Dosage regimens circulating online (typically 0.1–5 mg/dose) lack support from preclinical or clinical dose-finding studies. Furthermore, plasma half-life data are completely missing. Therefore, the use of Pinealon is essentially in a "not recommended due to insufficient evidence" state for all populations, rather than being limited to specific disease groups.
IV. Basic Safety Information: Limitations of In Vitro and Animal Studies
Pinealon's "good safety record" is entirely based on in vitro experiments and rodent models from the Khavinson Research Network. As a 418 Da tripeptide, it is expected to be rapidly degraded by endogenous peptidases, a characteristic that constitutes an inherent safety margin. However, long-term carcinogenicity, reproductive toxicity, and immunogenicity data are unavailable. Its binding to the CASP3 and APOE gene promoters suggests that its effects are highly dependent on the cellular context-neuroprotection in one cell type may translate into tumorigenesis or fibrosis in another.
Conclusion
Pinealon's list of contraindications is essentially a "list of unknowns." Its biggest reason for prohibition is not some specific toxicity, but the complete lack of basic safety data: no Phase I human trials, no pharmacokinetic profiles, no drug interaction data, and no long-term safety assessments. Pinealon should not be considered a viable treatment or health option by any individual until an independent, peer-reviewed Phase I clinical trial is completed. Its mechanistic biological activity is precisely the source of its unpredictable behavior in poorly characterized scenarios-a common characteristic of any candidate compound in research and development, not a unique case of Pinealon.
Important Disclaimer: Pinealon is a research chemical substance and has not been approved by the FDA, EMA, NMPA, or any regulatory agency for the treatment of human diseases. This information is for biomedical researchers' reference only and does not constitute any medication advice. All research activities must be conducted in a qualified laboratory and within an ethical review framework. The unauthorized procurement and use of products from unofficial channels for non-research purposes is strictly prohibited.